Panel Discussion: Genetics-Guided Risk Talks & Real-World Barriers: Driving Smarter Uptake of Disease-Modifying Therapies in Neurodegeneration
- Weighing how genetic risk factors such as APOE-ε4 in Alzheimer’s and LRRK2, GBA, or Parkin variants in Parkinson’s influence both treatment response and side-effect risk to help clinicians and patients make more informed therapy choices
- Examining real-world barriers to uptake of novel disease-modifying therapies across Alzheimer’s and Parkinson’s, including safety concerns (e.g., ARIA or off-target toxicities), monitoring burden, cost, and modest efficacy to highlight what truly drives or limits prescription and patient acceptance
- Knowing that earlier intervention before symptoms offers the greatest potential benefit, what screening or risk‑scoring approaches could expand pre‑symptomatic use while keeping the risk‑benefit ratio acceptable?